Picard Issues Statement on Intraday Stock Price
Rhea-AI Summary
Picard Medical (NYSE American: PMI) on October 24, 2025 said it is not aware of any undisclosed material change in its operations or financial condition that would explain recent intraday stock volatility. The company stated it remains focused on executing strategic and operational priorities and will continue to meet disclosure obligations under applicable securities laws.
Investors are directed to the company website and SEC filings for additional information.
Positive
- None.
Negative
- None.
News Market Reaction 42 Alerts
On the day this news was published, PMI declined 59.77%, reflecting a significant negative market reaction. Argus tracked a trough of -63.3% from its starting point during tracking. Our momentum scanner triggered 42 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $1.42B from the company's valuation, bringing the market cap to $955M at that time. Trading volume was exceptionally heavy at 8.5x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
TUCSON, Ariz., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart, today announced that it is not aware of any undisclosed material change in the Company’s operations or financial condition, that would account for the recent volatility in its stock price.
The Company remains focused on executing its strategic and operational priorities and will continue to comply with all disclosure obligations under applicable securities laws.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world. For more information, please visit https://www.syncardia.com
Forward-Looking Statements
This release may contain forward-looking statements within the meaning of federal securities laws. Such statements are based on current expectations and are subject to risks and uncertainties that may cause actual results to differ materially. The Company undertakes no obligation to update or revise any forward-looking statements.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
FAQ
What did Picard Medical (PMI) announce on October 24, 2025 about its stock price?
Does the October 24, 2025 Picard statement (PMI) include new financial results or guidance?
Where can investors find more information after Picard's October 24, 2025 statement (PMI)?
Will Picard (PMI) change its disclosure practices after the October 24, 2025 notice?
Should PMI shareholders expect operational changes after the October 24, 2025 statement?
